How Should We Measure Peripheral Spondyloarthritis?

REFERENCES

1. 1.↵
   1. Rudwaleit M,
   2. van der Heijde D,
   3. Landewe R, et al.

   The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25-31.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Mease P,
   2. Sieper J,
   3. Van den Bosch F,
   4. Rahman P,
   5. Karunaratne PM,
   6. Pangan AL.

   Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol 2015;67:914-23.

   OpenUrlPubMed
3. 3.↵
   1. Coates LC,
   2. Abraham S,
   3. Tillett W, et al.

   Performance and predictors of minimal disease activity response in peripheral spondyloarthritis patients treated with adalimumab. Arthritis Care Res 2020 Sep 16 (Epub ahead of print).
4. 4.↵
   1. Turina MC,
   2. Ramiro S,
   3. Baeten DL, et al.

   A psychometric analysis of outcome measures in peripheral spondyloarthritis. Ann Rheum Dis 2016;75:1302-7.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Beckers E,
   2. Been M,
   3. Webers C, et al.

   Performance of 3 composite measures for disease activity in peripheral spondyloarthritis. J Rheumatol 2022;49:256-64.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Taylor WJ,
   2. Harrison AA.

   Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 2004;51:311-5.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Fernandez-Sueiro JL,
   2. Willisch A,
   3. Pertega-Diaz S, et al.

   Validity of the Bath Ankylosing Spondylitis Disease Activity Index for the evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res 2010;62:78-85.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Poddubnyy D.

   Identifier NCT04434885. Axial involvement in Psoriatic Arthritis Cohort (AXIS). [Internet. Accessed September 20, 2021.] Available from: https://clinicaltrials.gov/ct2/show/NCT04434885
9. 9.↵
   1. Sacristan JA,
   2. Dilla T,
   3. Diaz-Cerezo S,
   4. Gabas-Rivera C,
   5. Aceituno S,
   6. Lizan L.

   Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature. PLoS One 2020;15:e0234705.

   OpenUrlPubMed
10. 10.↵
    1. Tillett W.

    Composite measures of impact and activity in psoriatic arthritis: a conceptual framework. J Rheumatol 2017;44:268-70.

    OpenUrlFREE Full Text
11. 11.↵
    1. Tillett W,
    2. McHugh N,
    3. Orbai AM, et al.

    Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership-recommended next steps. J Rheumatol Suppl 2020;96:11-8.

    OpenUrlAbstract/FREE Full Text